Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 481

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 481
---
 33

(Earnings per Share):

| (€ million)                                       |    2024 |    2023 |    2022 |
| Net income from discontinued  operations (Opella) |      64 |     338 |     401 |
| Average number of shares outstanding (million)    | 1,251.4 | 1,251.7 | 1,251.9 |
| Average number of shares after dilution (million) | 1,256.1 | 1,256.4 | 1,256.9 |
| Basic earnings per share (in euros)               |    0.04 |    0.25 |    0.31 |
| Diluted earnings per share (in euros)             |    0.04 |    0.25 |    0.31 |

| SANOFIFORM 20-F2024 | F-99 |

| NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS |

Off balance sheet commitments relating to Opella operating activities break down as follows:

| December 31, 2024                                              |       | Payments due by period |              |              |                  |
|:---------------------------------------------------------------|------:|-----------------------:|-------------:|-------------:|-----------------:|
| (€ million)                                                    | Total |        Less than1 year | 1 to 3 years | 3 to 5 years | More than5 years |
| Irrevocable purchase commitments                               |   704 |                    159 |          225 |          204 |              116 |
| •given                                                         |   705 |                    160 |          225 |          204 |              116 |
| •received                                                      |    -1 |                     -1 |              |              |                  |
| Research and development license agreements -commitments given |   676 |                      6 |          560 |           77 |               33 |
| Total                                                          | 1,380 |                    165 |          785 |          281 |              149 |

E/ Principal accountants’ fees and services

PricewaterhouseCoopers Audit and Forvis Mazars SA served as independent auditors of Sanofi for the year ended December 31,

2024 , and PricewaterhouseCoopers Audit and Ernst & Young in 2023. The table below shows fees charged by those firms and

member firms of their networks to Sanofi and consolidated subsidiaries in the years